Our approach targets O-acetylated GD2 (OAcGD2), a tumour-restricted antigen enabling more selective therapeutic strategies. We are advancing a focused pipeline in high-risk neuroblastoma and other solid tumour cancers with high unmet medical needs.
Neuroblastoma is an aggressive paediatric cancer arising from immature nerve cells. Current immunotherapies have significantly improved survival outcomes but remain difficult to tolerate. Many children experience severe pain and neurological side effects, which can limit dosing and increase overall treatment burden.
O-acetylated GD2 (OAcGD2) is a tumour-restricted variant of the clinically validated GD2 target. Unlike GD2, it is not detected in healthy peripheral nerve tissue but remains strongly expressed on tumour cells.
We have developed a proprietary antibody that selectively targets OAcGD2, with no cross-reactivity to GD2. This enables precise tumour targeting while sparing healthy tissues and reducing treatment burden for patients.
Improves tolerability
Promises improved efficacy
Enables outpatient treatment
Our proprietary antibody platform specifically targets OAcGD2, a tumour-restricted antigen. The lead programme focuses on high-risk neuroblastoma, where the need for safer, more tolerable treatments is most urgent. Building on this foundation, the platform is being expanded into additional OAcGD2 expressing tumours and alternative therapeutic formats.
*Programme licensed to Cellula Therapeutics (Remora Biotech company)
*Programme licensed to Cellula Therapeutics (Remora Biotech company)
With our lead OGD201 programme now in the IND-enabling stage, OGD2 Pharma is seeking strategic partners and co-investors to accelerate our clinical trajectory and ensure access for children with high-risk neuroblastoma.
Our proprietary OAcGD2-targeting platform additionally offers unique opportunities in other modalities, including antibody drug conjugates (ADCs), multispecific antibody formats, and chimeric antigen receptor (CAR) based cell therapies.
OGD2 Pharma, a venture of Remora Biotech, is a privately held biotechnology company headquartered in Nantes (France). The company is a carve-out of ATLAB Pharma, a previous Remora Biotech venture, which was acquired by Telix Pharmaceuticals in 2014.
Our vision is to lead the OAcGD2-targeting drug class, as the sole company developing proprietary antibodies against this novel antigen, and to establish a new generation of biotherapies for neuroblastoma and other OAcGD2-expressing cancers.
Thank you for your message. We have received your request and appreciate your interest in our services. Our team will review it and get back to you as soon as possible with a response.
We look forward to speaking with you soon.
Immunologist, entrepreneur, and investor with a long track record of translating immunology into medicines and building science-driven biotech companies.
Biotech executive with 15+ years of experience across advanced therapies, focused on strategy, operations, and strategic partnerships.
Expert in integrating preclinical science, regulatory strategy, and intellectual property to support clinical translation and asset differentiation.
Biopharma professional with 20+ years experience in drug development, CMC, regulatory affairs, and project leadership, combining scientific insight with strong team and program management.
A pioneer in cancer immunotherapy and Academician of Academia Sinica, Dr. Yu led dinutuximab from preclinical development through FDA approval in 2015, which established anti-GD2 therapy as standard of care for high-risk neuroblastoma. She is Professor Emeritus of Pediatrics at UC San Diego and Distinguished Chair Professor at Chang Gung Memorial Hospital. A long-standing member of the COG Neuroblastoma Steering Committee, she holds multiple distinguished awards including the 2025 Lifetime Achievement Award from Advances in Neuroblastoma Research and the 2020 ASCO Pediatric Oncology Award.
Dr. Dubois is Director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, leading programmes to advance targeted therapies for paediatric cancers. He holds a Master of Science in Epidemiology from Harvard School of Public Health and trained in paediatric oncology at Dana-Farber/Boston Children’s Hospital. His translational research focuses on neuroblastoma and Ewing sarcoma, spanning Phase I–III clinical trials and biomarker discovery. He has served on the Children’s Oncology Group Neuroblastoma Steering Committee, ASCO Scientific Program Committee, and the FDA Paediatric Oncology Drugs Advisory Committee.
Dr. Macy directs the Experimental Therapeutics Program at Children’s Hospital Colorado, the only early-phase paediatric oncology trial centre in the Rocky Mountain Region. She serves as institutional principal investigator for both the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and the New Agents in Neuroblastoma Therapy (NANT) consortium. Her research focuses on relapsed/refractory neuroblastoma, with leadership roles across multiple COG and NANT trials including ANBL1821, ANBL2421, and a novel international biomarker platform study. She also serves as Medical Director for the Colorado Child Health Research Institute, with a particular focus on precision medicine and high-risk therapeutics.
